CARDIOVASCULAR EVENT RISK REDUCTION WITH MEDICINES: DATA OF EVIDENCE BASED MEDICINE AND RECOMMENDATIONS TO PRACTITIONERS
Cardiovascular event risk reduction with medicines is discussed in the article. The role of randomized controlled trials is emphasized for estimation of therapy effects.
Main Author: | S. Y. Martsevich |
---|---|
Format: | Article |
Language: | English |
Published: |
Stolichnaya Izdatelskaya Kompaniya
2016-01-01
|
Series: | Racionalʹnaâ Farmakoterapiâ v Kardiologii |
Subjects: | |
Online Access: | https://www.rpcardio.com/jour/article/view/1142 |
Similar Items
-
Traditional Chinese Medicine Is Widely Used for Cardiovascular Disease
by: Yanwei Xing, MD, PhD, et al.
Published: (2018-05-01) -
Support of personalized medicine through risk-stratified treatment recommendations - an environmental scan of clinical practice guidelines
by: Yu Tsung, et al.
Published: (2013-01-01) -
Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
by: Volker Schirrmacher, et al.
Published: (2020-07-01) -
ACHIEVEMENT OF LIPID TARGET PLASMA LEVELS IN PATIENTS OF HIGH CARDIOVASCULAR RISK: IS MEDICINE CHOICE IMPORTANT?
by: S. Y. Martsevich, et al.
Published: (2016-01-01) -
A Cardiovascular Risk Score for Use in Occupational Medicine
by: Giuseppina Affinito, et al.
Published: (2021-06-01)